Effect of temozolomide on cell viability in gonadotroph adenoma cell lines

Oncology Reports

Volumn 26, Issue 3, 2011, Pages 543-550

  Ma, Sihai ^a   Liu, Xiaohai ^a   Yao, Yong ^a   Cai, Feng ^a   Dai, Congxin ^a   Bao, Xinjie ^a   Feng, Ming ^a   Wei, Junji ^a   Zhang, Bo ^b   Li, Guilin ^a   Ma, Wenbin ^a   Wang, Renzhi ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

T3 1; Apoptosis; Gonadotroph adenoma; Temozolomide

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; DEATH RECEPTOR; DIMETHYL SULFOXIDE; FOLLITROPIN; LUTEINIZING HORMONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; TEMOZOLOMIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; GONADOTROPH ADENOMA; HORMONE RELEASE; INCUBATION TIME; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CELL;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; ENZYME ACTIVATION; FOLLICLE STIMULATING HORMONE; GONADOTROPHS; LUTEINIZING HORMONE; MICE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 79959972136     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1317     Document Type: Article

References (33)

1. Selman WR, Laws ER Jr, Scheithauer BW and Carpenter SM: The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64: 402-407, 1986. (Pubitemid 16035061)
2. Asa SL and Ezzat S: The pathogenesis of pituitary tumours. Nat Rev Cancer 2: 836-849, 2002.
3. Korbonits M and Carlsen E: Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res 71 (Suppl 2): 123-130, 2009.
4. Ho DM, Hsu CY, Ting LT and Chiang H: The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases. Hum Pathol 28: 905-911, 1997. (Pubitemid 27355550)
5. Snyder PJ: Gonadotroph cell adenomas of the pituitary. Endocr Rev 6: 552-563, 1985.
6. Delellis RA, Lloyd RV, Heitz PU and Eng C: Pathology and genetics of tumours of endocrine organs. World Health Organization, IARC Press, Lyon, pp270-311, 2004.
7. Chanson P: Gonadotroph pituitary adenomas. Ann Endocrinol (Paris) 61: 258-268, 2000.
8. Bei R, Marzocchella L and Turriziani M: The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. Recent Pat Anticancer Drug Discov 5: 172-187, 2010.
9. Kulke MH, Chan JA, Meyerhardt JA, et al: A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol: [Epub ahead of print October 20, 2010. doi: 10.1007/s00280-010-1478-7].
10. Syro LV, Ortiz LD, Scheithauer BW, et al: Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117 454-462, 2010.
11. Bush ZM, Longtine JA, Cunningham T, et al: Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with 0(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95: E280-E290, 2010.
12. Raverot G, Sturm N, de Fraipont F, et al: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95: 4592-4599, 2010.
13. Mohammed S, Kovacs K, Mason W, Smyth H and Cusimano MD: Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64: E773-E774, 2009.
14. Lim S, Shahinian H, Maya MM, Yong W and Heaney AP: Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7: 518-520, 2006. (Pubitemid 43796152)
15. Fadul CE, Kominsky AL, Meyer LP, et al: Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105: 621-626, 2006. (Pubitemid 44525896)
16. Syro LV, Scheithauer BW, Ortiz LD, et al: Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens) 8: 303-306, 2009.
17. Sheehan J, Rainey J, Nguyen J, Grimsdale R and Han S: Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg 114: 354-358, 2011.
18. Morin E, Berthelet F, Weisnagel J, Bidlingmaier M and Serri O: Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary: [Epub ahead of print April 21, 2010. doi: 10.1007/S11102-010-0232-9].
19. Windle JJ, Weiner RI and Mellon PL: Cell lines of the pituitary gonadotrope lineage derived by targeted oncogenesis in transgenic mice. Mol Endocrinol 4: 597-603, 1990.
20. Kaina B, Fritz G, Mitra S and Coquerelle T: Transfection and expression of human 06-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12: 1857-1867, 1991.
21. VillanoJL, Seery TE and Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64: 647-655, 2009.
22. Pepponi R, Marra G, Fuggetta MP, et al: The effect of 06-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)l-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304: 661-668, 2003. (Pubitemid 36152342)
23. D'Atri S, Tentori L, Lacal PM, et al: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341, 1998. (Pubitemid 28368823)
24. Tisdale MJ: Antitumour i midazotetrazines-XI: effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1, 2,3,5- tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism. Br J Cancer 52: 789-792, 1985.
25. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273: 33533-33539, 1998. (Pubitemid 29005737)
26. Ochs K and Kaina B: Apoptosis induced by DNA damage 06-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/ caspase-8 independent. Cancer Res 60: 5815-5824, 2000.
27. Roos WP, Batista LF, Naumann SC, et al: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion 06-methylguanine. Oncogene 26: 186-197, 2007. (Pubitemid 46095730)
28. Djerassi A, Coutifaris C, West VA, et al: Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab 80: 591-594, 1995.
29. Catargi B, Felicie-Dellan E and Tabarin A: Comment on gonadotroph adenoma causing ovarian hyperstimulation. J Clin Endocrinol Metab 84: 3404, 1999. (Pubitemid 30646981)
30. Murata Y, Ando H, Nagasaka T, et al: Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 88: 1988-1993, 2003.
31. Murakami T, Higashitsuji H, Yoshinaga K, Terada Y, Ito K and Ikeda H: Management of ovarian hyperstimulation due to follicle-stimulating hormone-secreting gonadotroph adenoma. BJOG 111: 1297-1300, 2004. (Pubitemid 39472180)
32. Hammond LA, Eckardt JR, Kuhn JG, et al: A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-l-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 10: 1645-1656, 2004. (Pubitemid 38435554)
33. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y and Fine RL: Temozolomide (Temodar(R)) and capecitabine (Xeloda(R)) treatment of an aggressive corticotroph pituitary tumor. Pituitary: [Epub ahead of print December 4, 2009 doi: 10.1007/s11102-009-0211-1].